Gordon KB, et al. - The efficacy of guselkumab was contemplated in this trial in patient subgroups with moderate-to-severe psoriasis, from the pooled guselkumab VOYAGE 1 and VOYAGE 2 Phase 3 studies. A high degree of efficacy was illustrated with the guselkumab therapy compared with placebo at week 16 and with adalimumab at week 24 among broad subpopulations of patients with varying baseline demographics, disease characteristics, and previous psoriasis treatments.